GET DAILY SIGNALSAvalo Therapeutics (AVTX) Stock Drops -36% Over 30 Days on IL-1β Sentiment Shift
Key Takeaways
- Avalo Therapeutics shares fell about 36% over the trailing 30 days, from a closing price of $11.84 on October 14 to roughly $7.57.
- The decline was driven primarily by mixed Phase 3 results from AbbVie's ABBV lutikizumab in hidradenitis suppurativa, which pressured sentiment across the IL-1β drug class.
- Several analysts reacted in the aftermath: Guggenheim downgraded the stock to Neutral, while Oppenheimer cut its price target from $35 to $16 but kept an Outperform rating.
- Over the trailing quarter, the stock has fallen roughly 60%, extending a longer downtrend from its 52-week closing high of $22.87 set in May 2026.
- Avalo's lead candidate abdakibart reported positive Phase 2 LOTUS topline data, with a registrational Phase 3 program planned for the first half of 2027.
- The company held $472.2 million in cash, cash equivalents, and investments as of June 30, 2026, which management expects to fund operations into 2029.
- For additional detail, explore Avalo's Price Targets, Earnings, and Forecast pages for deeper analysis of the stock.
Avalo Therapeutics (AVTX) Company Overview
Avalo Therapeutics is a clinical-stage biotechnology company focused on treatments targeting the IL-1β pathway for immune-mediated inflammatory diseases. Its lead asset, abdakibart, is an anti-IL-1β monoclonal antibody advancing toward a Phase 3 registrational program in hidradenitis suppurativa, a chronic inflammatory skin condition affecting an estimated 1–4% of the global population. The firm is also developing AVTX-010, a long-acting next-generation anti-IL-1β antibody aimed at longer dosing intervals. Formerly known as Cerecor, it rebranded in August 2021 and is based in Wayne, Pennsylvania. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
AVTX Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, Avalo Therapeutics shares declined approximately 36%, moving from a closing price of $11.84 on October 14 to around $7.57. The sharpest single-day move occurred on October 22, when the stock fell roughly 40% in one session in response to external clinical data from a competitor. The quarterly trend has been even more pronounced. Roughly three months earlier, the stock was trading near $19.45, meaning AVTX has shed about 60% over the trailing quarter. This extends a longer decline from the stock's 52-week closing high of $22.87 reached on May 7, 2026.
What Drove the Recent Price Action in AVTX
The primary catalyst behind the recent move was external to Avalo. In mid-October 2026, ABBV AbbVie reported results from its Phase 3 INTREPID trial of lutikizumab in hidradenitis suppurativa. While the study met its primary endpoint, it demonstrated only about an 8-percentage-point placebo-adjusted improvement on the HiSCR75 measure at week 16, a result widely characterized as among the weaker Phase 3 efficacy outcomes seen in the indication. Because lutikizumab inhibits both IL-1α and IL-1β, while Avalo's abdakibart targets only IL-1β, investors interpreted the results as raising the risk that IL-1β blockade alone may be insufficient to drive strong efficacy in HS. This triggered a sharp sell-off in Avalo shares and a wave of analyst revisions. Guggenheim downgraded the stock to Neutral and removed its price target, while Oppenheimer cut its target from $35 to $16 while retaining an Outperform rating. H.C. Wainwright and Cantor Fitzgerald, by contrast, maintained their positive ratings and reiterated support for the company's development strategy.
Broader Context Behind the Quarterly Decline
The quarterly decline reflects a broader reassessment of the IL-1β opportunity in hidradenitis suppurativa rather than any change in Avalo's own clinical data. The company's Phase 2 LOTUS trial of abdakibart produced positive topline results, and management has outlined a plan to advance the candidate into a registrational Phase 3 program in the first half of 2027. However, the stock had already been drifting lower from its spring highs before the October catalyst, as investors weighed competitive dynamics in the HS space, including data from rivals such as UCB's Bimzelx. The October readout from AbbVie compounded these concerns, compressing valuation multiples and pushing the stock toward the low end of its 52-week range.
Key Drivers to Monitor for AVTX Going Forward
Looking ahead, the most important catalysts for Avalo center on the advancement of its pipeline. The planned initiation of a registrational Phase 3 program for abdakibart in hidradenitis suppurativa, expected in the first half of 2027, is the key near-term milestone. Investors will also monitor the company's submission of an Investigational New Drug application for AVTX-010, likewise targeted for the first half of 2027. Beyond company-specific events, the stock is likely to remain sensitive to competitive data in the HS and broader IL-1β space, as well as to analyst revisions that reassess the probability of success for IL-1β monotherapy. Quarterly financial results will provide further visibility into research and development spending and the company's cash runway, which management has guided into 2029.
Using Tickeron’s Trending AI Robots for Additional Perspective
In my view, one resource worth exploring alongside fundamental analysis is Tickeron’s Trending AI Robots page, which curates top-performing automated trading strategies across thousands of tickers. It highlights bots that meet performance and relevance criteria, offering a range of approaches without needing to review the full catalog. This can complement research on names like AVTX by surfacing data-driven signals in a systematic way.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AVTX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for AVTX turned positive on November 06, 2026. Looking at past instances where AVTX's MACD turned positive, the stock continued to rise in 42 of 48 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AVTX's RSI Oscillator exited the oversold zone, 32 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on AVTX as a result. In 63 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
Following a +9.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVTX advanced for three days, in 199 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 54 cases where AVTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
The 50-day moving average for AVTX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
AVTX broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AVTX entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. AVTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.828) is normal, around the industry mean (3.498). P/E Ratio (-1.571) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (19.030) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. AVTX's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical stage biopharmaceutical company
Industry Biotechnology
Advertisement